Quarterly report pursuant to Section 13 or 15(d)

Net loss per share (Details) - Schedule of antidilutive securities excluded from computation of earnings per share

v3.22.1
Net loss per share (Details) - Schedule of antidilutive securities excluded from computation of earnings per share - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Schedule of antidilutive securities excluded from computation of earnings per share [Abstract]    
Options to purchase common stock 1,187,085 684,322
Warrants to purchase common stock (in Dollars) $ 4,784,193
Total 5,971,278 684,322